Impaired prolactin responsiveness to a dopamine antagonist in long-term survivors of acute lymphoblastic leukaemia.
Cranial irradiation is known to affect the neuroendocrine control of GH secretion. The aim of the present study was to clarify the effect of leukaemia treatment on neuroendocrine control of PRL secretion in long-term survivors of acute lymphoblastic leukaemia (ALL). Pituitary LH, FSH and PRL responses to GnRH and to the dopamine receptor antagonist metoclopramide were evaluated in 18 boys 1.6-9 years after discontinuation of medication for ALL. All the boys had been subjected to prophylactic cranial irradiation and 8 to testicular irradiation. Eight of the boys had supranormal gonadotropin levels either basally or after GnRH. All had normal basal PRL levels, but in 14 of the 18 boys the metoclopramide-releasable PRL levels were subnormal. The decreased PRL responses cannot be explained by the hypergonadotropism, since exaggerated rather than decreased responses are frequently found in patients with primary gonadal failure. We conclude that abnormal regulation of PRL secretion is a frequent consequence of treatment of ALL, probably being due to decreased pituitary lactotrop mass.
D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007945:Leukemia, Lymphoid / Q000378:metabolism / Q000628:therapy*; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology*; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology*; D011379:Prognosis; D011388:Prolactin / Q000378:metabolism*; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents; D010906:Pituitary Hormone-Releasing Hormones; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008787:Metoclopramide